|
|
|
Teva Pharmaceutical Industries Limited (NYSE: TEVA) |
|
|
|
| |
Teva Pharmaceutical Industries Limited Outlook |
On December 20 2024 the Teva Pharmaceutical Industries Limited provided following guidance
nnTeva Pharmaceutical Industries Limitednn is set to provide an update on its financial performance and expectations for the future in a significant conference call. The company has announced that it will release its financial results for the fourth quarter and the full year of 2024, alongside its financial outlook for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. Eastern Time.
Investors and s alike are keenly awaiting this announcement, as the details regarding the financial guidance for 2025 will be disclosed during the event. While Teva has confirmed that it will offer insights into its future financial outlook, it has yet to provide any specific figures or projections. This lack of detailed information has heightened anticipation among stakeholders.
Following the press release, Teva will host a conference call and live webcast at 8:00 a.m. ET on the same day. During this session, executives will discuss the financial results and further elaborate on the guidance for the upcoming year. This event is expected to be beneficial for those monitoring the company's trajectory and assessing its strategic direction in the pharmaceutical market.
The conference will be an important opportunity for participants to gain a deeper understanding of Teva's performance, its challenges, and the strategies it plans to implement moving forward into 2025.,
|
On November 6 2024 the Teva Pharmaceutical Industries Limited provided following guidance
Teva Pharmaceutical Industries Limited has shared robust financial results for the third quarter of 2024, predominantly driven by impressive performance in its generics sector and significant growth within its innovative product portfolio. In light of these strong results, the company has upgraded its financial guidance for 2024, anticipating increases in key metrics such as revenues, adjusted EBITDA, and non-GAAP earnings per share (EPS).
While the specific numerical forecasts for these financial indicators were not disclosed in the announcement, the overall tone indicates a positive trajectory for Teva's financial health and operational efficiency. This revised outlook reflects the company's commitment to its strategic objectives and ability to adapt in a competitive market landscape.
For further details and an accessible version of the press release, please visit [www.tevapharm.com](https://www.globenewswire.com/Tracker?data=gL5LsJT7dyFGcN_KkP1AkFPYO0WwHHjbp8Xm5CCPEt7jAC1A83tVlGLr_JkFQfjH_EaW6XYROyNJqVHkvdVOS2K5pzMqdfz3TltyU_kE12A=).,
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
